JP2023549547A5 - - Google Patents
Info
- Publication number
- JP2023549547A5 JP2023549547A5 JP2023529022A JP2023529022A JP2023549547A5 JP 2023549547 A5 JP2023549547 A5 JP 2023549547A5 JP 2023529022 A JP2023529022 A JP 2023529022A JP 2023529022 A JP2023529022 A JP 2023529022A JP 2023549547 A5 JP2023549547 A5 JP 2023549547A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- compound
- groups
- optionally substituted
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063115552P | 2020-11-18 | 2020-11-18 | |
| US63/115,552 | 2020-11-18 | ||
| PCT/US2021/072475 WO2022109573A1 (en) | 2020-11-18 | 2021-11-17 | Macrocycles containing a 1,3,4-oxadiazole ring for use as modulators of cystic fibrosis transmembrane conductance regulator |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023549547A JP2023549547A (ja) | 2023-11-27 |
| JP2023549547A5 true JP2023549547A5 (enExample) | 2024-11-26 |
Family
ID=79602287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023529022A Pending JP2023549547A (ja) | 2020-11-18 | 2021-11-17 | 嚢胞性線維症膜コンダクタンス制御因子のモジュレーターとして使用するための１，３，４－オキサジアゾール環を含有する大環状化合物 |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP4247817A1 (enExample) |
| JP (1) | JP2023549547A (enExample) |
| KR (1) | KR20230123522A (enExample) |
| CN (1) | CN116670140A (enExample) |
| AR (1) | AR124090A1 (enExample) |
| AU (1) | AU2021383176A1 (enExample) |
| CA (1) | CA3201793A1 (enExample) |
| CL (1) | CL2023001398A1 (enExample) |
| CO (1) | CO2023007896A2 (enExample) |
| CR (1) | CR20230260A (enExample) |
| DO (1) | DOP2023000099A (enExample) |
| EC (1) | ECSP23045439A (enExample) |
| GE (1) | GEAP202316271A (enExample) |
| IL (1) | IL302873A (enExample) |
| JO (1) | JOP20230105A1 (enExample) |
| MX (1) | MX2023005721A (enExample) |
| PE (1) | PE20231380A1 (enExample) |
| WO (1) | WO2022109573A1 (enExample) |
| ZA (1) | ZA202305296B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021113808A1 (en) | 2019-12-05 | 2021-06-10 | Genzyme Corporation | Cftr-modulating arylamides |
| WO2021113806A1 (en) | 2019-12-05 | 2021-06-10 | Genzyme Corporation | Arylamides and methods of use thereof |
| WO2021113809A1 (en) | 2019-12-05 | 2021-06-10 | Genzyme Corporation | Arylamides and methods of use thereof |
| CR20230120A (es) | 2020-08-07 | 2023-09-01 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| US12324802B2 (en) | 2020-11-18 | 2025-06-10 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| CN119095597A (zh) * | 2022-02-03 | 2024-12-06 | 弗特克斯药品有限公司 | 治疗囊性纤维化的方法 |
| CA3251045A1 (en) * | 2022-02-08 | 2023-08-17 | Vertex Pharmaceuticals Incorporated | MODULATORS OF THE TRANSMEMBRANE CONDUCTANCE REGULATOR IN CYSTIC FIBROSIS |
| AU2023273614A1 (en) * | 2022-05-16 | 2024-11-07 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| US20250340568A1 (en) | 2022-05-16 | 2025-11-06 | Vertex Pharmaceuticals Incorporated | Solid forms of a macrocyclic compounds as cftr modulators and their preparation |
| WO2024054851A1 (en) * | 2022-09-07 | 2024-03-14 | Sionna Therapeutics | Macrocyclic compounds, compositions and methods of using thereof |
| IL319374A (en) | 2022-09-07 | 2025-05-01 | Sionna Therapeutics Inc | Macrocyclic compounds, compositions and methods of using them |
| WO2024056798A1 (en) | 2022-09-15 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | Macrocyclic cftr modulators |
| CN119907667A (zh) * | 2022-09-15 | 2025-04-29 | 爱杜西亚药品有限公司 | 大环cftr调节剂与cftr校正剂和/或cftr增效剂的组合 |
| CA3267791A1 (en) | 2022-09-15 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | CRYSTALLINE FORM OF (3S,7S,10R,13R)-13-BENZYL-20-FLUORO-7-ISOBUTYL-N-(2-(3-METHOXY-1,2,4-OXADIAZOL-5-YL)ETHYL)-6,9-DIMETHYL-1,5,8,11-TETRAOXO-10-(2,2,2-TRIFLUOROETHYL)-1,2,3,4,5,6,7,8,9,10,11,12,13,14-TETRADECAHYDRO-[1]OXA[4,7,10,14]TETRAAZACYCLOHEPTADECINO [16,17-F]QUINOLINE-3-CARBOXAMIDE |
| IL327468A (en) | 2023-10-04 | 2026-05-01 | Vertex Pharma | Solid forms of cystic fibrosis transmembrane conductance regulator |
| CN122374316A (zh) | 2023-10-04 | 2026-07-10 | 弗特克斯药品有限公司 | 囊性纤维化跨膜传导调控因子的调节剂 |
| WO2025186214A1 (en) | 2024-03-05 | 2025-09-12 | Idorsia Pharmaceuticals Ltd | Macrocyclic cftr modulators |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103946221B (zh) * | 2011-09-16 | 2016-08-03 | 诺华股份有限公司 | 用于治疗囊性纤维化的杂环化合物 |
| GEP20217329B (en) * | 2016-09-30 | 2021-12-10 | Vertex Pharma | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| EA202192783A1 (ru) * | 2016-12-09 | 2022-02-24 | Вертекс Фармасьютикалз Инкорпорейтед | Модулятор регулятора трансмембранной проводимости при муковисцидозе, фармацевтические композиции, способы лечения и способ получения указанного модулятора |
| TWI810243B (zh) * | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| RS64018B1 (sr) * | 2018-02-15 | 2023-03-31 | Vertex Pharma | Makrocikli kao modulatori transmembranskog regulatora provodnosti cistične fibroze, njihove farmaceutske kompozicije, njihova upotreba u lečenju cistične fibroze i proces njihove izrade |
| CN109134431B (zh) * | 2018-10-10 | 2021-06-04 | 成都理工大学 | 作为囊性纤维化跨膜传导调节因子抑制剂的氨基咪唑偶联吡啶酮衍生物 |
| TWI848092B (zh) * | 2019-04-03 | 2024-07-11 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白調節劑 |
-
2021
- 2021-11-17 PE PE2023001653A patent/PE20231380A1/es unknown
- 2021-11-17 CN CN202180090910.1A patent/CN116670140A/zh active Pending
- 2021-11-17 EP EP21843853.9A patent/EP4247817A1/en active Pending
- 2021-11-17 AU AU2021383176A patent/AU2021383176A1/en active Pending
- 2021-11-17 KR KR1020237020002A patent/KR20230123522A/ko active Pending
- 2021-11-17 GE GEAP202316271A patent/GEAP202316271A/en unknown
- 2021-11-17 JP JP2023529022A patent/JP2023549547A/ja active Pending
- 2021-11-17 CA CA3201793A patent/CA3201793A1/en active Pending
- 2021-11-17 WO PCT/US2021/072475 patent/WO2022109573A1/en not_active Ceased
- 2021-11-17 IL IL302873A patent/IL302873A/en unknown
- 2021-11-17 CR CR20230260A patent/CR20230260A/es unknown
- 2021-11-17 MX MX2023005721A patent/MX2023005721A/es unknown
- 2021-11-18 AR ARP210103184A patent/AR124090A1/es unknown
-
2023
- 2023-05-11 JO JOJO/P/2023/0105A patent/JOP20230105A1/ar unknown
- 2023-05-15 ZA ZA2023/05296A patent/ZA202305296B/en unknown
- 2023-05-16 CL CL2023001398A patent/CL2023001398A1/es unknown
- 2023-05-17 DO DO2023000099A patent/DOP2023000099A/es unknown
- 2023-06-16 CO CONC2023/0007896A patent/CO2023007896A2/es unknown
- 2023-06-16 EC ECSENADI202345439A patent/ECSP23045439A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010536887A5 (enExample) | ||
| HRP20250694T1 (hr) | Modulatori regulatora transmembranske provodljivosti cistične fibroze | |
| JP2013530179A5 (enExample) | ||
| JP2012500260A5 (enExample) | ||
| ES2293530T3 (es) | Derivados de sulfonamidas para el tratamiento de enfermedades. | |
| RU2014115290A (ru) | Производные 1-фенил 2-пиридинилалкиловых спиртов в качестве ингибиторов | |
| JP2010511626A5 (enExample) | ||
| RU2001132635A (ru) | Производные пиперидина, применимые в качестве антагонистов сс R5 | |
| IL302873A (en) | Macrocycles Containing a 1,3,4-OXADIAZOLE Ring for Use as Cystic Fibrosis Conductance Modulators | |
| JP2020510015A5 (enExample) | ||
| JP2015501833A5 (enExample) | ||
| JP2019529490A5 (enExample) | ||
| RU2014121090A (ru) | Модуляторы рецептора нмда и их применение | |
| JP2014517017A5 (ja) | 化合物、その医薬組成物、及び癌治療用の阻害薬としてのその使用 | |
| JP2009518296A5 (enExample) | ||
| RU2006129312A (ru) | Производные ариланилина в качестве агонистов 2 адренергического рецептора | |
| JP2004516314A5 (enExample) | ||
| JP2016501250A5 (enExample) | ||
| JP2014015465A5 (enExample) | ||
| RU2015121046A (ru) | Соединения, обладающие активностью антагонистов мускариновых рецепторов и агонистов бета-2-адренергических рецепторов | |
| JP2021501756A5 (enExample) | ||
| JP2021535177A5 (enExample) | ||
| JP2017525699A5 (enExample) | ||
| JP2020521772A5 (enExample) | ||
| RU2008151761A (ru) | Производные имидазоазепинона |